REVB · Revelation Biosciences, Inc. · Insider Trading

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

Represents the weighted-average price at which shares were purchased within a range between $1.14 and $1.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options vest and become exercisable on the grant date.

The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

Represents the weighted-average price at which shares were purchased within a range between $2.53 and $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

The original Form 4, filed on February 8, 2022, is being amended by this Form 4 amendment to include shares purchased directly that were inadvertently omitted in the original filing.